Ignite Creation Date:
2024-05-06 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 12:50 PM
Study NCT ID:
NCT03614949
Status:
RECRUITING
Last Update Posted:
2024-03-21
First Post:
2018-07-30
Brief Title:
SBRT and Atezolizumab in the Management of Recurrent Persistent or Metastatic Cervical Cancer
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Phase II Study of Stereotactic Body Radiation Therapy and Atezolizumab in the Management of Recurrent Persistent or Metastatic Cervical Cancer
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy SBRT will improve the objective response rate ORR compared with atezolizumab alone in patients with recurrent persistent or metastatic cervical cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ML40521 | OTHER | Genentech | None |